Synthesis and structure-activity relationship in a class of indolebutylpiperazines as dual 5-HT1A receptor agonists and serotonin reuptake inhibitors

Journal of Medicinal Chemistry

Volumn 47, Issue 19, 2004, Pages 4684-4692

  Heinrich, Timo ^a   Böttcher, Henning ^a   Gericke, Rolf ^a   Bartoszyk, Gerd D ^a   Anzali, Soheila ^a   Seyfried, Christoph A ^a   Greiner, Hartmut E ^a   Van Amsterdam, Christoph ^a  

^a MERCK KGAA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 BENZOFURANYL 2 CARBOXAMIDE; AMIDE; CHLORAMPHETAMINE; DOPAMINE 2 RECEPTOR; EPTAPIRONE; FLUORINE; INDOLE DERIVATIVE; INDOLEBUTYLPIPERAZINE DERIVATIVE; IPSAPIRONE; NITRILE; PINDOLOL; PIPERAZINE DERIVATIVE; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; VILAZODONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BIOISOSTERISM; CALCULATION; CONTROLLED STUDY; DIPOLE; DRUG SELECTIVITY; DRUG SYNTHESIS; ELECTRIC POTENTIAL; ELECTRON; EX VIVO STUDY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; ULTRASOUND; VOCALIZATION;

ANIMALS; BIOLOGICAL TRANSPORT; HIPPOCAMPUS; INDOLES; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; PIPERAZINES; RATS; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 4444353338     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040793q     Document Type: Article

References (50)

1. 1A Receptor Ligands in Animal Models of Anxiety, Impulsivity and Depression: Multiple Mechanisms of Action? Prog. Neuro-Psychopharmacol. Biol. Psychiatry 1993, 17, 87-104.
2. (b) Murasaki, M.; Miura, S. The Future of 5-HT Receptor Agonists (Aryl-Piperazine Derivatives). Prog. Neuro-Psychopharmacol. Biol. Psychiatry 1992, 16, 833-845.
3. (a) Lapierre, Y. D.; Silverstone, P.; Reesal, R. T.; Saxena, B.; Turner, P.; Bakish, D.; Plamondon, J.; Vincent, P. M.; Remick, R. A.; Kroft, C.; Payer, R.; Resales, D.; Lam, R.; Bologa, M. A Canadian Mulitcenter Study of Three Fixed Doses of Controlled-Release Ipsapirone in Outpatiants with Moderate to Severe Major Depression. J. Clin. Psychopharmacol. 1998, 18, 268-273.
4. 1A Receptor Affinity of 1-Phenyl-4-[ω-(α- or β-tetralinyl)alkyl]piperazines. J. Med. Chem. 1996, 39, 4928-4934.
5. 1A Receptor Agonist with Marked Anxiolytic and Antidepressant Potential. J. Pharmacol. Exp. Ther. 1998, 287, 266-283.
6. (a) Spinks, D.; Spinks, G. Serotonin Re-Uptake Inhibition: An Update on Current Research Strategies. Curr. Med. Chem. 2002, 9, 799-810.
7. (b) Pacher, P.; Kohegyi, E.; Kecskemeti, V.; Furst, S. Current Trends in the Development of New Antidepressants. Curr. Med. Chem. 2001, 8, 89-100.
8. (c) Schechter, L. E.; McGonigle, P.; Barrett, J. E. Serotonergic Antidepressants: Current and Future Perspectives. Curr. Opin. Cent. Peripher. Nerv. Syst. Invest. Drugs 1999, 1, 432-447.
9. (d) Evrard, D. A.; Harrison, B. L. Recent Approaches to Noval Antidepressant Therapy. Annu. Rep. Med. Chem. 1999, 34, 1-10.
10. 1A Receptor Antagonists as Putative Adjuvants to Antidepressants: Clinical and Preclinical Evidence. IDrugs 1999, 2, 121-128.
11. 1A Receptor Antagonism/SSRI Activities. Part 1. Bioorg. Med. Chem. Lett. 2003, 13, 1903-1905.
12. 1A Serotonin Receptors and Serotonin Transporter as a New Class of Antidepressants. Eur. J. Med. Chem. 2001, 36, 55-61.
13. 1A Serotonin Receptors and Serotonin Transporter, as a New Class of Antidepressants. J. Med. Chem. 2001, 44, 418-428.
14. (d) Meagher, K. L.; Mewshaw, R. E.; Evrard, D. A.; Zhou, P.; Smith, D. L.; Scerni, R.; Spangler, T.; Abulhawa, S.; Shi, X.; Schechter, L. E.; Andree, T. H. Studies towards the Next Generation of Antidepressants. Part 1: Indolylcyclohexylamines as Potent Serotonin Reuptake Inhibitors. Bioorg. Med. Chem. Lett. 2001, 11, 1885-1888.
15. 1A Receptors. J. Med. Chem. 2002, 45, 4128-4139.
16. 1A receptors. Eur. J. Pharmacol. 2002, 442, 63-71.
17. 1A Agonists. J. Med. Chem. 2004, 47, 4677-4683.
18. (a) Böttcher, H.; Barnickel, G.; Hausberg, H.-H.; Haase, A. F.; Seyfried, C. A.; Eiermann, V. Synthesis and Dopaminergic Activity of Some 3-(1,2,3,6-Tetrahydro-1-pyridylalkyl)indoles. A Novel Conformational Model To Explain Structure-Activity Relationships. J. Med. Chem. 1992, 35, 4020-4026.
19. (b) Seyfried, C. A.; Fuxe, K.; Wolf, H.-P.; Agnati, L. F. Demonstration of a New Type of Dopamine Receptor Agonist: An Indole-3-butyl-amine. Action at Intact Versus Supersensitive Dopamine Receptors in the Rat Forebrain. Acta Physiol. Scand. 1982, 116, 465-468.
20. (c) Hausberg, H.-H.; Böttcher, H.; Fuchs, A.; Gottschlich, R.; Koppe, V.; Minck, K.-O.; Pötsch, E.; Saiko, O.; Seyfried, C. A. Indole-alkyl-piperidines, a New Class of Dopamine Agonists. Acta Pharm. Suec. (Suppl.) 1983, 2, 213-217.
21. 2-Autoreceptor Agonists, with Special Reference to Indol-butyl-amines. Drugs Future 1990, 15, 819-832.
22. Oh, S. J.; Ha, H.-J.; Chi, D. Y.; Lee, H. K. Serotonin Receptor and Transporter Ligands-Current Status. Curr. Med. Chem. 2001, 5, 999-1034.
23. Clark, R. D.; Repke, D. B. Some Observations on the Formation of Hydroxy-Indoles in the Leimgruber-Batcho Indole Synthesis. J. Heterocycl. Chem. 1985, 22, 121-125.
24. Egawa, H.; Kataoka, M.; Shibamori, K.-i.; Miyamoto, T.; Nakano, J.; Matsumoto, J.-i. Pyridonecarboxylic Acid Antibacterial Agents. Part 7. A New Synthetic Route to 7-Halo-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxoquinoline-3- caroxylic Acid, an Intermediate for the Synthesis of Quinolone Antibacterial Agents. J. Heterocycl. Chem. 1987, 24, 181-185.
25. Prelog, V.; Driza, G. J. Bis(β-haloethyl)amines III. N-Phenyl-Piperazines. Collect. Czech. Chem. Commun. 1933, 5, 497-502.
26. Mukaiyama, T. New Synthetic Methods. 29. New Syntheses with Onium Salts of Azaarenes. Angew. Chem. 1979, 91, 798-812 [IE 1979, 18, 707-721].
27. Mukaiyama, T. New Synthetic Methods. 29. New Syntheses with Onium Salts of Azaarenes. Angew. Chem. 1979, 91, 798-812 [IE 1979, 18, 707-721].
28. 1B/1D Antagonistic Activity: A New Approach toward Efficient Antidepressants. J. Med. Chem. 2000, 43, 1149-1157.
29. 2 Dopamine Receptors, Respectively. J. Neurochem. 1986, 46, 1058-1067.
30. 3H-Spiroperidol Labels Dopamine Receptors in Pituitary and Brain. Eur. J. Pharmacol. 1977, 46, 377-381.
31. Wong, D. T.; Bymaster, F. P.; Mayle, D. A.; Reid, L. R.; Krushinski, J. H. Robertson, D. W. LY248686, a New Inhibitor of Serotonin and Norephedrine Uptake. Neuropsychopharmacology 1993, 8, 23-33.
32. Fuller, R. W.; Snoddy, H. D.; Snoddy, A. M.; Hemrick, S. K.; Wong, D. T.; Molloy, B. B. p-Iodoamphetamine as a Serotonin Depletor in Rats. J. Pharmacol. Exp. Ther. 1980, 212, 115-119.
33. 1A Receptors. Eur. J. Pharmacol. 1996, 307, 107-111.
34. 1A Receptor Agonistic Properties. Eur. J. Pharmacol. 1997, 322, 147-153.
35. De Vry, J.; Benz, U.; Schreiber, R.; Traber, J. Shock-Induced Ultrasonic Vocalization in Young Adult Rats: A Model for Testing Putative Anti-Anxiety Drugs. Eur. J. Pharmacol. 1993, 249, 331-339.
36. Protais, P.; Costentin. J.; Schwartz, J. C. Climbing Behaviour Induced by Apomorphine in Mice, a Simple Test for the Study of Dopamine Receptors in Striatum. Psychopharmacology 1976, 50, 1-6.
37. 2 Autoreceptor Agonist. J. Pharmacol. Exp. Ther. 1996, 276, 41-48.
38. (a) Graham, J. E.; Ripley, D. C.; Smith, J. T.; Vedene, H., Jr.; Weaver, D. F. Theoretical Studies Applied to Drug Design. Ab Initio Electronic Distributions in Bioisosters. THEOCHEM 1995, 343, 105-109.
39. (b) Parr, R. G.; Pearson, R. G. Absolute Hardness: Companion Parameter to Absolute Electronegativity. J. Am. Chem. Soc. 1983, 705, 7512-7516.
40. (c) Thornber, C. W. Isosterism and Molecular Modification in Drug Design. Chem Soc. Rev. 1979, 8, 563-580.
41. Stewart, J. PM3 calculation. Mopac, version 6.00 (QCPE no. 455) distributed with Sybyl, version 6.8 (Tripos Associates).
42. 2 Pharmacophores. X-Ray Structures and Affinities of Conformationally Constrained Ligands. J. Med. Chem. 1993, 36, 1301-1315.
43. 1A Receptor Binding Modes of the Enantiomers of 5-OMe-DPAT. Bioorg. Med. Chem. Lett. 1999, 7, 1805-1820.
44. Bartoszyk, G. D.; Barber, A.; Böttcher, H.; Greiner, H. E.; Leibrock, J.; Martinez, J. M.; Seyfried, C. A. Soc. Neurosci. Abstr. 1996, 22, 613.
45. Page, M. E.; Cryan, J. F.; Sullivan, A.; Dalvi, A.; Saucy, B.; Manning, D. R.; Lucki, I. Behavioral and Neurochemical Effects of 5-{4-[4-(5-Cyano-3- indolyl)-butyl)-butyl]-1-piperazinyl}-benzofuran-2-carboxamide (EMD 68843): A Combined Selective Inhibitor of Serotonin Reuptake and 5-Hydroxytrvptamine 1A Receptor Partial Agonist. J. Pharmacol. Exp. Ther. 2002, 302, 1220-1228.
46. Nishiyama, M.; Yamamoto, T.; Koie, Y. Synthesis of N-Arylpiperazines from Aryl Halides and Piperazine under a Palladium Tri-tert-butylphosphine Catalyst. Tetrahedron Lett. 1998, 39, 617-620.
47. 3H]5-Methoxy-3-(di-n-propylamino)chroman. Eur. J. Pharmacol. 1987, 140, 143-155.
48. Whittaker, V. P. The synaptosome. In Handbook of Neurochemistry; Laiths, A., Ed.; Plenum Press: London and New York, 1969; pp 327-364.
49. Seyfried, C. A.; Greiner, H. E.; Haase, A. F. Biochemical and Functional Studies on EMD 49980: A Potent, Selectively Presynaptic D-2 Dopamine Agonist with Actions on Serotonin Systems. Eur. J. Pharmacol. 1989, 160, 31-41.
50. 3H] in Various Regions of the Brain. J. Neurochem. 1966, 13, 655-669.